These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31954159)

  • 1. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer.
    Zeng Z; Wang ZY; Li YK; Ye DM; Zeng J; Hu JL; Chen PF; Xiao J; Zou J; Li ZH
    Life Sci; 2020 Aug; 254():117325. PubMed ID: 31954159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
    Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
    Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features.
    Solis LM; Behrens C; Dong W; Suraokar M; Ozburn NC; Moran CA; Corvalan AH; Biswal S; Swisher SG; Bekele BN; Minna JD; Stewart DJ; Wistuba II
    Clin Cancer Res; 2010 Jul; 16(14):3743-53. PubMed ID: 20534738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks.
    Xu K; Ma J; Hall SRR; Peng RW; Yang H; Yao F
    Theranostics; 2023; 13(2):704-723. PubMed ID: 36632216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging roles of Nrf2 signal in non-small cell lung cancer.
    Tian Y; Liu Q; He X; Yuan X; Chen Y; Chu Q; Wu K
    J Hematol Oncol; 2016 Feb; 9():14. PubMed ID: 26922479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nrf2 regulates cell motility through RhoA-ROCK1 signalling in non-small-cell lung cancer cells.
    Ko E; Kim D; Min DW; Kwon SH; Lee JY
    Sci Rep; 2021 Jan; 11(1):1247. PubMed ID: 33441941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC.
    Ji L; Zhang R; Chen J; Xue Q; Moghal N; Tsao MS
    Sci Rep; 2019 Aug; 9(1):12437. PubMed ID: 31455821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity.
    Zhu J; Wang H; Chen F; Lv H; Xu Z; Fu J; Hou Y; Xu Y; Pi J
    Toxicol Appl Pharmacol; 2018 Nov; 358():1-9. PubMed ID: 30196066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of NRF2 in Lung Cancer.
    Sánchez-Ortega M; Carrera AC; Garrido A
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nestin regulates cellular redox homeostasis in lung cancer through the Keap1-Nrf2 feedback loop.
    Wang J; Lu Q; Cai J; Wang Y; Lai X; Qiu Y; Huang Y; Ke Q; Zhang Y; Guan Y; Wu H; Wang Y; Liu X; Shi Y; Zhang K; Wang M; Peng Xiang A
    Nat Commun; 2019 Nov; 10(1):5043. PubMed ID: 31695040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-wide global identification of NRF2 binding sites in A549 non-small cell lung cancer cells by ChIP-Seq reveals NRF2 regulation of genes involved in focal adhesion pathways.
    Namani A; Liu K; Wang S; Zhou X; Liao Y; Wang H; Wang XJ; Tang X
    Aging (Albany NY); 2019 Dec; 11(24):12600-12623. PubMed ID: 31884422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAQR4 promotes chemoresistance in non-small cell lung cancer through inhibiting Nrf2 protein degradation.
    Xu P; Jiang L; Yang Y; Wu M; Liu B; Shi Y; Shen Q; Jiang X; He Y; Cheng D; Xiong Q; Yang Z; Duan L; Lin J; Zhao S; Shi P; Yang C; Chen Y
    Theranostics; 2020; 10(8):3767-3778. PubMed ID: 32206121
    [No Abstract]   [Full Text] [Related]  

  • 16. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
    Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
    Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer.
    Tian Y; Wu K; Liu Q; Han N; Zhang L; Chu Q; Chen Y
    J Hematol Oncol; 2016 Sep; 9(1):83. PubMed ID: 27601007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors.
    Singh A; Venkannagari S; Oh KH; Zhang YQ; Rohde JM; Liu L; Nimmagadda S; Sudini K; Brimacombe KR; Gajghate S; Ma J; Wang A; Xu X; Shahane SA; Xia M; Woo J; Mensah GA; Wang Z; Ferrer M; Gabrielson E; Li Z; Rastinejad F; Shen M; Boxer MB; Biswal S
    ACS Chem Biol; 2016 Nov; 11(11):3214-3225. PubMed ID: 27552339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment.
    Best SA; De Souza DP; Kersbergen A; Policheni AN; Dayalan S; Tull D; Rathi V; Gray DH; Ritchie ME; McConville MJ; Sutherland KD
    Cell Metab; 2018 Apr; 27(4):935-943.e4. PubMed ID: 29526543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the cell signaling pathway Keap1-Nrf2 as a therapeutic strategy for adenocarcinomas of the lung.
    Zhang B; Ma Z; Tan B; Lin N
    Expert Opin Ther Targets; 2019 Mar; 23(3):241-250. PubMed ID: 30556750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.